Plus500 grants 462,656 shares worth £16.9 million to executives and staff through RSUs, LTIP awards, and deferred bonuses.
Plus500 grants 462,656 shares worth £16.9 million to executives and staff through RSUs, LTIP awards, and deferred bonuses.
Plus500 grants 462,656 shares worth £16.9 million to executives and staff through RSUs, LTIP awards, and deferred bonuses.
Key points:
Israel-based CFDs broker Plus500 (LON: PLUS) announced that on 31 December 2025, it granted Restricted Share Units (RSUs), Long-Term Incentive Plan (LTIP) awards, and ordinary shares under its 2026 deferred bonus scheme. The company also made the grants in line with previous years and tied them to remuneration packages for the 2026 financial year.
The total awards amount to 462,656 Plus500 shares, valued at approximately £16.9 million, or $22.7 million, at current prices.
Plus500 issued 100,148 RSUs over ordinary shares to certain Persons Discharging Managerial Responsibilities (PDMRs) and their closely associated persons. It also granted 233,190 RSUs to employees across the group. Each RSU gives the holder an unsecured right to receive one ordinary share on the settlement date, subject to performance conditions.
In addition, the company awarded LTIP rights covering 277,594 ordinary shares to executive directors and PDMRs. These awards will vest on 31 December 2028, with the final number of shares determined using a reference price of 1,467 pence per share, adjusted for shareholder returns. Plus500 also allocated 185,062 ordinary shares under its 2026 deferred bonus scheme, calculated using the same reference price.
Chief Executive Officer David Zruia and Chief Financial Officer Elad Even-Chen received the largest allocations. Furthermore, each executive will receive 231,328 ordinary shares, valued at about $11.4 million, through a combination of LTIP awards and deferred bonuses. Other senior recipients include CMO Nir Zatz, CTO Al Yaros, Chief Regulation Officer Yevgeni Shtuckmeyster, Plus500 Israel CEO Erez Levy, Chief People Officer Eden Dahan, and VP of R&D Or Rotem.
Also, visit the Stock Broker Talks website for more insights and Reviews.